On June 10, 2025, HC Wainwright & Co. reaffirmed its optimistic outlook on Lipocine (LPCN, Financial) by reiterating a 'Buy' rating. Analyst Yi Chen maintained the price target at $8.00 USD, consistent with previous assessments.
The reaffirmation from HC Wainwright & Co. underscores continued confidence in LPCN's market potential. The analyst's consistent price target suggests an anticipated stable upward trajectory for Lipocine in the coming fiscal period.
Investors keeping track of LPCN should note the sustained positive sentiment from one of Wall Street's notable analyst firms, reinforcing the optimism surrounding Lipocine's future performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Lipocine Inc (LPCN, Financial) is $7.38 with a high estimate of $8.00 and a low estimate of $6.75. The average target implies an upside of 118.84% from the current price of $3.37. More detailed estimate data can be found on the Lipocine Inc (LPCN) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Lipocine Inc's (LPCN, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
